Strathclyde to add drug royalty exposure after below-benchmark returns
Scheme invests in fund specialising in purchasing drug royalty agreements between pharmaceutical companies, smaller developers
You have now reached your article limit
Already a registered user or member? Sign in here
To continue reading, register free today for access
Registration also includes access to
Five reasons to register today
- Access to IPE articles from our award-winning editorial team
- Unique IPE market data, rankings and tables
- In-depth interviews with pension fund leaders
- Extensive coverage of latest asset class trends
- Comprehensive archive of data, research and intelligence
Copyright © 1997–2025 IPE International Publishers Limited, Registered in England, Reg No. 3233596, VAT No. 685 1784 92. Registered Office: 1 Kentish Buildings, 125 Borough High Street, London SE1 1NP